WKL Stock Analysis: Wolters Kluwer | AS
Specialty Business Services | AS, Netherlands | Market Cap: 17.163m EUR | 12M Return: -25.5% | NL0000395903 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 83.6M
EPS Trend: -22.9%
Rev. Trend: 94.3%
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Wolters Kluwer N.V. (WKL) is a Dutch professional information and software company founded in 1836 and headquartered in Alphen aan den Rijn, the Netherlands. It operates five reporting segments: Health; Tax & Accounting; Financial & Corporate Compliance; Legal & Regulatory; and Corporate Performance & ESG. Customers span hospitals, tax and accounting firms, financial institutions, law firms, corporations, government agencies, and universities across Europe, North America, and Asia Pacific.
The business model centers on B2B subscriptions and licenses for regulatory, clinical, tax, legal, and compliance content and workflow software, with the company increasingly layering cloud delivery and AI features (including GenAI and agentic tools) on top of its established information databases. Its products are typically mission-critical inputs for professional decision-making, which underpins high renewal rates and recurring revenue.
Under GICS classification, Wolters Kluwer sits in the Industrials sector / Diversified Support Services sub-industry and is listed as a Large Cap on Euronext Amsterdam. It is generally grouped with other listed Dutch-originated professional information providers such as RELX and Elseviers parent, reflecting a concentrated European presence in legal, scientific, and regulatory publishing.
- Health segment GenAI solutions drive recurring revenue growth
- Regulatory compliance demand boosts Financial & Corporate Compliance segment
- ESG reporting requirements expand Corporate Performance & ESG segment
| Net Income: 1.33b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.14 > 0.02 and ΔFCF/TA -3.69 > 1.0 |
| NWC/Revenue: -23.52% < 20% (prev -17.39%; Δ -6.12% < -1%) |
| CFO/TA 0.17 > 3% & CFO 1.69b > Net Income 1.33b |
| Net Debt (4.24b) to EBITDA (2.00b): 2.11 < 3 |
| Current Ratio: 0.69 > 1.5 & < 3 |
| Outstanding Shares: last quarter (225.3m) vs 12m ago -8.41% < -2% |
| Gross Margin: 74.07% > 18% (prev 64.77%; Δ 9.31% > 0.5%) |
| Asset Turnover: 61.11% > 50% (prev 62.44%; Δ -1.34% > 0%) |
| Interest Coverage Ratio: 14.34 > 6 (EBIT TTM 1.56b / Interest Expense TTM 109.0m) |
| A: -0.14 (Total Current Assets 3.17b - Total Current Liabilities 4.61b) / Total Assets 10.3b |
| B: 0.11 (Retained Earnings 1.17b / Total Assets 10.3b) |
| C: 0.16 (EBIT TTM 1.56b / Avg Total Assets 9.99b) |
| D: 0.10 (Book Value of Equity 940.0m / Total Liabilities 9.31b) |
| Altman-Z'' = 0.61 = B |
| DSRI: 1.00 (Receivables 1.61b/1.60b, Revenue 6.11b/6.08b) |
| GMI: 0.87 (GM 64.77% / 74.07%) |
| AQI: 0.94 (AQ_t 0.67 / AQ_t-1 0.71) |
| SGI: 1.00 (Revenue 6.11b / 6.08b) |
| TATA: -0.03 (NI 1.33b - CFO 1.69b) / TA 10.3b) |
| Beneish M = -3.17 (Cap -4..+1) = AA |
As of October 14, 2026, the stock is trading at EUR 78.84 with a total of 1,395,266 shares traded. Over the past week, the price has changed by +13.67%, over one month by +11.48%, over three months by +28.09% and over the past year by -25.49%.
Current recommended Stop Loss: 76.00 (which is 3.6% or 1.2 ATR below the current price).
Wolters Kluwer has no consensus analysts rating.
P/E Trailing = 13.1897
P/E Forward = 10.5263
P/S = 2.8109
P/B = 15.9731
P/EG = 1.6985
Revenue TTM = 6.11b EUR
EBIT TTM = 1.56b EUR
EBITDA TTM = 2.00b EUR
Long Term Debt = 3.94b EUR (from longTermDebt, last quarter)
Short Term Debt = 1.33b EUR (from shortTermDebt, last quarter)
Debt = 5.73b EUR (from shortLongTermDebtTotal, last quarter) + Leases 205.0m
Net Debt = 4.24b EUR (calculated: Debt 5.73b - CCE 1.49b)
Enterprise Value = 21.4b EUR (17.2b + Debt 5.73b - CCE 1.49b)
Interest Coverage Ratio = 14.34 (Ebit TTM 1.56b / Interest Expense TTM 109.0m)
EV/FCF = 15.35x (Enterprise Value 21.4b / FCF TTM 1.39b)
FCF Yield = 6.51% (FCF TTM 1.39b / Enterprise Value 21.4b)
FCF Margin = 22.83% (FCF TTM 1.39b / Revenue TTM 6.11b)
Net Margin = 21.86% (Net Income TTM 1.33b / Revenue TTM 6.11b)
Gross Margin = 74.07% ((Revenue TTM 6.11b - Cost of Revenue TTM 1.58b) / Revenue TTM)
Gross Margin QoQ = 74.41% (prev 73.74%)
Tobins Q-Ratio = 2.09 (Enterprise Value 21.4b / Total Assets 10.3b)
Interest Expense / Debt = 1.90% (Interest Expense 109.0m / Debt 5.73b)
Taxrate = 20.63% (347.0m / 1.68b)
NOPAT = 1.24b (EBIT 1.56b * (1 - 20.63%))
Current Ratio = 0.69 (Total Current Assets 3.17b / Total Current Liabilities 4.61b)
Debt / Equity = 6.09 (Debt 5.73b / totalStockholderEquity, last quarter 940.0m)
Debt / EBITDA = 2.11 (Net Debt 4.24b / EBITDA 2.00b)
Debt / FCF = 3.04 (Net Debt 4.24b / FCF TTM 1.39b)
Total Stockholder Equity = 1.04b (last 4 quarters mean from totalStockholderEquity)
RoA = 13.36% (Net Income 1.33b / Total Assets 10.3b)
RoE = 128.1% (Net Income TTM 1.33b / Total Stockholder Equity 1.04b)
RoCE = 31.36% (EBIT 1.56b / Capital Employed (Equity 1.04b + L.T.Debt 3.94b))
RoIC = 18.59% (NOPAT 1.24b / Invested Capital 6.67b)
WACC = 4.30% (E(17.2b)/V(22.9b) * Re(5.23%) + D(5.73b)/V(22.9b) * Rd(1.90%) * (1-Tc(0.21)))
Discount Rate = 5.23% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -99.04 | Cagr: -6.32%
[DCF] Terminal Value 73.10% ; FCFF base≈1.51b ; Y1≈1.32b ; Y5≈1.07b
[DCF] Fair Price = 58.12 (EV 17.2b - Net Debt 4.24b = Equity 12.9b / Shares 222.4m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: -22.92 | EPS CAGR: -2.90% | SUE: N/A | # QB: 0
Revenue Correlation: 94.32 | Revenue CAGR: 3.86% | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=5.60 | Chg30d=+0.11% | Revisions=-17% | GrowthEPS=+5.9% | GrowthRev=+2.5%
EPS next Year (2027-12-31): EPS=6.19 | Chg30d=-0.28% | Revisions=-57% | GrowthEPS=+10.4% | GrowthRev=+5.6%
[Analyst] Revisions Ratio: -50% (up=1, down=6)